was there a mechanism to revoke FDA approval or take drugs off the market if scientific studies by academics proved them to be without benefit. An in-depth data investigation by the Milwaukee Journal Sentinel and MedPageToday in 2014 revealed that, thanks to surrogate endpoints, 74 percent of cancer drugs approved by the FDA during the previous decade ultimately did not extend life by even a single day.
